Nucleic Acid Transfer Development Program
LAMELLASOME™ Nucleic Acid Transfer Technology
LAMELLASOME™ technology is a proprietary Nucleic Acid Transfer platform with the capability to deliver a spectrum of active agents from microRNAs to plasmids.
LAMELLASOME™ CF-NA is a LAMELLASOME™/plasmid treatment targeted at functional CFTR replacement therapy for Cystic Fibrosis.
Lamellar has data to prove that LAMELLASOME™ CF-NA provides safe and effective delivery of functional plasmid to lungs in vivo, while avoiding gene therapy-associated immune response.
LAMELLASOME™ IPF-NA is a LAMELLASOME™/microRNA product that is being developed for the treatment of idiopathic pulmonary fibrosis.
Lamellar has shown that the miR is safely and effectively delivered by LAMELLASOME™ and that it has a significant downstream antifibrotic effect, demonstrated as a marked reduction in IPF biomarkers. All transfected cells demonstrated high transfection, high cell viability and maintenance of cell phenotype.
Other Development Programs
As well as LAMELLASOME™ Nucleic Acid Transfer technology, Lamellar are involved in other areas of research investigating the capabilities of our proprietary LAMELLASOME™ technology. These other research programs include anti-fibrotic, anti-infective, and drug delivery products.
If you would like to learn more about these other developments, please contact us.